Uy Ear
Stock Analyst at Mizuho Securities
(4.21)
# 1,504
Out of 4,463 analysts
583
Total ratings
45.2%
Success rate
8.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Reiterated: Buy | $53 → $65 | $51.72 | +25.68% | 58 | Jul 1, 2026 | |
| EOLS Evolus | Reiterated: Buy | $15 | $6.74 | +122.55% | 49 | Jul 1, 2026 | |
| QURE uniQure | Reiterated: Buy | $35 → $68 | $45.17 | +50.54% | 26 | Jun 24, 2026 | |
| SLGL Sol-Gel Technologies | Initiated Coverage: Buy | $285 | $71.99 | +295.89% | 1 | Jun 24, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | $57 | $55.92 | +1.93% | 11 | Jun 12, 2026 | |
| TECX Tectonic Therapeutic | Reiterated: Buy | $85 | $32.87 | +158.59% | 34 | Jun 10, 2026 | |
| RNAC Cartesian Therapeutics | Reiterated: Buy | $40 | $10.18 | +292.93% | 28 | Jun 9, 2026 | |
| ARQT Arcutis Biotherapeutics | Reiterated: Buy | $35 | $25.84 | +35.45% | 161 | Jun 3, 2026 | |
| INAB IN8bio | Reiterated: Buy | $4 | $1.42 | +181.69% | 16 | Jun 1, 2026 | |
| RLMD Relmada Therapeutics | Reiterated: Buy | $19 | $6.39 | +197.34% | 36 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $25.20 | +38.89% | 38 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $31 | $18.20 | +70.33% | 63 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $146 → $175 | $167.77 | +4.31% | 38 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.48 | n/a | 13 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.99 | n/a | 9 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $14 | $4.12 | n/a | 1 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $14 | $33.44 | n/a | 1 | Jul 10, 2019 |
Alkermes
Jul 1, 2026
Reiterated: Buy
Price Target: $53 → $65
Current: $51.72
Upside: +25.68%
Evolus
Jul 1, 2026
Reiterated: Buy
Price Target: $15
Current: $6.74
Upside: +122.55%
uniQure
Jun 24, 2026
Reiterated: Buy
Price Target: $35 → $68
Current: $45.17
Upside: +50.54%
Sol-Gel Technologies
Jun 24, 2026
Initiated Coverage: Buy
Price Target: $285
Current: $71.99
Upside: +295.89%
MBX Biosciences
Jun 12, 2026
Reiterated: Buy
Price Target: $57
Current: $55.92
Upside: +1.93%
Tectonic Therapeutic
Jun 10, 2026
Reiterated: Buy
Price Target: $85
Current: $32.87
Upside: +158.59%
Cartesian Therapeutics
Jun 9, 2026
Reiterated: Buy
Price Target: $40
Current: $10.18
Upside: +292.93%
Arcutis Biotherapeutics
Jun 3, 2026
Reiterated: Buy
Price Target: $35
Current: $25.84
Upside: +35.45%
IN8bio
Jun 1, 2026
Reiterated: Buy
Price Target: $4
Current: $1.42
Upside: +181.69%
Relmada Therapeutics
May 14, 2026
Reiterated: Buy
Price Target: $19
Current: $6.39
Upside: +197.34%
May 7, 2026
Reiterated: Buy
Price Target: $35
Current: $25.20
Upside: +38.89%
May 6, 2026
Reiterated: Buy
Price Target: $31
Current: $18.20
Upside: +70.33%
Dec 12, 2025
Maintained: Hold
Price Target: $146 → $175
Current: $167.77
Upside: +4.31%
Aug 18, 2023
Rated: Hold
Price Target: n/a
Current: $1.48
Upside: n/a
Aug 11, 2023
Rated: Hold
Price Target: n/a
Current: $2.99
Upside: n/a
Jul 10, 2019
Initiated Coverage: Hold
Price Target: $14
Current: $4.12
Upside: n/a
Jul 10, 2019
Initiated Coverage: Hold
Price Target: $14
Current: $33.44
Upside: n/a